Reviewer #1 (TAK1/TAB signaling)(Remarks to the Author):
-The study completely neglects the importance of linear (M1) ubiquitination for NF-kB signalling. CYPJ maybe interferes with K63-Ub signaling, however, M1 signaling at least needs to be discussed here. To me a sublethal dose is a dose to which WT mice all survive. I propose to lower the dose of LPS. Also: how do mice respond to a sublethal dose of TNF ?
Minor comments: -TNFα should be replaced by TNF (since TNFβ has been renamed to LT). -Page 7, lines 139 and 144 : treatment of cells with Il-1β (and not IL-6). Fig. 7 Response: We thank the reviewer's concern. The unapparent differences between wild type and Cypj-deficient mice are largely due to the improper condition used in previous assay. We optimized the dose of these inflammatory reagents and presented better results in this revised manuscript.
The in vivo data shown in
In sub-lethal dose of 10 mg/kg LPS experiment, only 1 mouse died in WT group (1/6) within 48 h compared to 5 mice died in KO group (5/6; Fig.7a) . In another experiment, we intraperitoneally injected LPS at 0 h (5 mg/kg) and 72 h (50 mg/kg) sequentially as shown in Supplementary Fig. 11a , and the data showed that all WT mice remained alive while 4 out of 7 KO mice died. In both endotoxin shock assays, the survival times between WT and KO mice are statistically significant, indicating Cypj plays important roles in vivo.
Compared to well established negative regulators, although the weight loss between WT and Cypj-KO mice looks less significant in DSS model (Fig. 7e) , morphology and histological analyses showed that Cypj deficiency resulted in severer atrophy and disruption of mucosal structures of the colons (Fig. 7f, g) . Moreover, the function of Cypj is comparable to that of newly identified inflammation resolver Tet2 (Zhang Q, et al. Tet 2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6. 2015 Nature 525, 389-393, figure 1g ). In addition, we used HKLM (heat killed Listeria Monocytogenes) to induce systematic inflammation. Intraperitoneal injection of HKLM (2×10 12 CFU/mouse) showed that WT mice were all alive after 7 days while 4 out of 7 KO mice died (Fig.7d) . Taken these in vivo data together, we concluded that Cypj is a new negative regulator of inflammation. Figure S1C demonstrates Response: We agree with the reviewer that it's important to compare the activity of CYPJ with other cyclophilins, such as CYPA.
Supplementary
In the revised manuscript, we provided evidences to show that the protein abundance of both CYPJ and CYPA are induced by inflammatory stimulations such as TNF-α (Fig. 1i) , LPS ( Fig. 1j) and VSV infection (Fig. 1k) . Luciferase assay showed that CYPJ and CYPA, as well as their catalytic dead mutants, attenuate TNF-α induced NF-κB activation ( Supplementary Fig. 1c ). We deleted CYPA in genome of 293T cells by CRISPR-Cas9 technique ( Supplementary Fig. 1f , inset), and found that CYPA deficiency significantly enhanced NF-κB activation ( Supplementary Fig. 1f ), TNF-α and IL-8 transcription (Supplementary Fig. 1g ) and IKKα/β and IκBα phosphorylation ( Supplementary Fig. 1i ) induced by TNF-α. Furthermore, we silenced Cypa or Cypj expression in mBMM cells by siRNA ( Supplementary Fig. 4a, 4b ). Compared to si-NC group, both Cypa and Cypj knockdown promoted secretion of proinflammatory cytokines Tnf-α and Il-6 ( Supplementary Fig. 4c, 4d ). Based on these observations, we conclude that CYPJ and CYPA are negative regulators of NF-κB signaling pathway.
In this manuscript we provided a mechanism that CYPJ binds to NZF domain of TAB2 and TAB3 thus disrupts the recruitment of K63-Ub chain and inhibits NF-κB signaling. As the reviewer questioned whether CYPA shared similar mechanism, we performed GST pull-down assay to address this issue. As shown in Fig. 4c , 293T expressed HA-CYPA does not bind to bacterially expressed and purified GST-NZF domain of TAB2, TAB3 or NEMO. At the mean time, CYPA does not interact with TAB2 or TAB3 in co-IP assays (Supplementary Fig. 7f ). These results suggest that the mechanism of CYPA is distinct from that of CYPJ in regulating NF-κB. Fig. 3D are not compelling to demonstrate the interaction between TAB2/TAB3 and CYPJ at endogenous protein levels. Reciprocal immunoprecipitation and a time course analysis should be provided.
While overexpressed CYPJ is clearly capable of binding to TAB2/TAB3, the results in

Response:
We appreciate the reviewer's concern. We performed endogenous co-IP to confirm the interaction between CYPJ and TAB2/3 (Fig. 3d) . 293T cells were treated with TNF-α for different times, and cell lysates were carried out for immunoprecipitation (IP) with anti-TAB2 or anti-TAB3 antibody. The amount of CYPJ forms complex with TAB2/3 was detected by WB using an anti-CYPJ antibody. The results confirmed endogenous interaction between CYPJ and TAB2/3, and the binding between these molecules increased with TNF-α treatment in a time dependent manner (Fig. 3d) . Unfortunately we cannot find an anti-CYPJ antibody suitable for immunoprecipitation, so it is regrettable that the reciprocal co-IP could not be carried out.
Ubiquitin binding data are all used overexpressed ubiquitin, which is not sufficient. A time course analysis of how TNF-induced TAB2/3 binding to poly-ubiquitin chain is changed in wild type and Cypj-deficient cells should be examined without exogenous proteins.
Response: We thank the reviewer's constructive concern. We generated CYPJ-deficient 293T cells by CRISPR-Cas9, and treated WT and KO cells with TNF-α for 0, 10 or 20 min. Then endogenous TAB2 was immunoprecipitated by an anti-TAB2 antibody and its associated K63-Ub chains were detected by a K63-Ub specific antibody. As shown in Fig.  5c , CYPJ deficiency increased TNF-α induced endogenous K63-Ub signal of TAB2.
The authors should also test whether CYPJ does not alter interaction between TAB2/3 and TAK1.
Response: We appreciate the reviewer's suggestion. We performed competitive co-IP in 293T cells transfected with plasmids as indicated in Supplementary Fig. 8 . The results showed that all proteins were successfully expressed and CYPJ overexpression does not affect the interaction between TAK1-TAB2 (Supplementary Fig. 8a ) and TAK1-TAB3 (Supplementary Fig. 8b ).
Other concerns i) Fig.4 and 5 should include the input protein levels of ubiquitin (poly ubiquitin chain). ii) Fig. 2D--CYPJ immunoblotting should be included. The upregulation of IKK activation by Cypj deficiency is marginal, which does not support the conclusion. iii) The title is misleading. The results do not show that CYPJ disrupts poly-ubiquitin chain iv) Cecum seems to be very small in Cypj deficient mice, which is unusual and needs a discussion. ii) Editing is required.
Response: We thank the reviewer's helpful concerns. i) The figures need to include input ubiquitin levels are mainly in Fig. 5 and 6 . We found out the input samples from -80 freezer, and performed WB using anti-HA to detect overexpressed Ub (Fig. 5a, b, g and Fig. 6g, h) . Besides, we also detected the endogenous ubiquitin using an antibody that specifically recognizes K63-Ub chain (Fig. 5c) . ii) We purchased a new antibody to detect the endogenous Cypj (ABGENT AP17078b, C-term) and using samples of Fig. 2d , f, h and Supplementary Fig. 3c stored in -80℃ freezer. The levels of P-Ikkα/β and Ikkα/β were detected at the mean time by WB. The results showed that the Cypj expression is absent in KO mBMMs, and P-Ikkα/β is significantly higher in KO cells in response to LPS (Fig 2d) , Tnf-α (Fig  2f) , HKLM (Fig 2h) or Il-1β (Supplementary Fig. 3c ). These results support our conclusion that Cypj is a negative regulator of NF-κB signaling. iii) In this manuscript, we provided evidences to show that CYPJ disrupts the interaction between K63-Ub-chain and NZF domains of TAB2/3 (Fig. 5) . In these experiments, we also included synthesized K63-Ub-chain in several experiments to do in vitro binding assay with E.coli-expressed and purified CYPJ and NZF (Fig. 5e,f) . The results showed that CYPJ reduces the binding of K63-Ub-chain to TAB2/3-NZF in a cell-free system (Fig. 5e,f) . As these results strongly support our conclusion, we did not change the title of our manuscript. iv) The size of cecum between WT and KO mice without DSS treatment is similar (Supplementary Fig. 11b ). The possible reason for the size of cecum looks smaller in KO group in Fig. 7f is that DSS induced stronger intestinal inflammation and severer diarrhea in KO mice, which resulted in less fecal storage in cecum. v) We carefully revised the manuscript. The quality of the language has been largely improved.
Reviewer #2:
1. The study is informative and data are overall convincing. However, the manuscript is poorly written with lots of grammatical and linguistic mistakes.
Response:
We carefully revised the manuscript and largely improved the quality of the language.
The study completely neglects the importance of linear (M1) ubiquitination for NF-kB signaling. CYPJ maybe interferes with K63-Ub signaling, however, M1 signaling at least needs to be discussed here.
Response: We appreciate the reviewer's suggestion. We modified Fig.4d and added new experiments in Supplementary Fig.9 to evaluate the regulation of M1 ubiquitination.
We expressed and purified GST-fused NZF of HOIP-1, HOIP-2, HOIL, SHARPIN and NEMO from E.coli, and subsequently incubated these proteins with recombinant His-CYPJ in GST pull-down assay (Fig.4d) . His-CYPJ binds to HOIP-2 and SHARPIN with higher affinity (Fig.4d) , and the interaction between CYPJ and HOIP was confirmed by reciprocal co-IP experiments (Supplementary Fig. 9a ). These results suggest that CYPJ forms complex with LUBAC (linear ubiquitin chain assembly complex) in cells.
Next, we investigated the regulation of CYPJ on LUBAC. HA-CYPJ overexpression in 293T cells largely reduced linear ubiquitination of NEMO, which is a major substrate of LUBAC (Supplementary Fig. 9b ). As predicted, CYPJ enforced expression attenuates HOIP induced NF-kB activation (Supplementary Fig. 9c ). All these experiments indicated that CYPJ is a negative regulator of M1 ubiquitination.
3. Fig. 1g : nuclear p65 staining unclear to me.
Response:
We performed the experiment again and replaced Fig.1g for better resolution.
Fig. 1i : CYPJ expression is induced after stimulation of Hela, BMM and A549 cells : is CYPJ an NF-kB response gene ?
Response: We appreciate the reviewer's concern. We found out samples of Fig. 1i-1k from -80 freezer and evaluated the mRNA abundance of CYPJ and its paralogous gene CYPA in response to inflammatory stimulations for different time (Supplementary Fig.  2) . Although under these conditions the transcription of NF-kB downstream targets TNF-α, IL-8 or Il-6 were significantly induced, we are interested to find that the mRNA levels of CYPJ and CYPA kept unchanged (Supplementary Fig. 2) . However, the protein of CYPJ and CYPA are induced (Fig. 1i-1k) . These results suggest that CYPJ and CYPA are inflammation response proteins but the regulation is at post-transcription level. In other words, we cannot categorize CYPJ and CYPA to targets of NF-kB. The mechanism for inflammation induced expression of CYPJ and CYPA protein needs further study.
Fig. 2d, f, h : the authors need to confirm absence of CYPJ expression in CRISPR knockout cells (Western blots). Page 12 "CRISPR-Cas9 edition results in a truncated form of CYPJ" : this is nowhere shown. Did the authors generate a knockout of a truncated CYPJ ?
Response: We appreciate the reviewer's suggestion. From the schematic diagram of Fig.  2a , CRISPR-Cas9 genomic edition results in an in-frame stop codon at the 18th amino acids of Cypj. We found out the previous input samples and detected Cypj expression using a new CYPJ antibody (ABGENT AP17078b, C-term). As shown in Fig. 2d , f, h and Supplementary Fig. 3a , the full-length of Cypj expression is detected in WT mBMMs but is absent in KO cells. So we deleted the sentence "CRISPR-Cas9 edition results in a truncated form of CYPJ" from the revised manuscript which may mislead readers.
6. Fig. 5d : not convincing. Hard to believe the statement that CYPJ blocks the binding of TAB2 to K63-Ub based on these data.
Response: In Fig. 5d , we observed that less Flag-TAB2 binds to His-K63-chain in the presence of HA-CYPJ enforced expressed in 293T cells. In order to provide more evidences to support this conclusion, we added synthesized K63-Ub-chain to do in vitro binding assay with E.coli-expressed and purified His-CYPJ and GST-NZF. The results of Fig. 5e and 5f show that the amount of TAB2/3-NZF bound His-K63-chain is largely decreased in the present of CYPJ in a cell-free system. These results confirmed that CYPJ blocks the interaction between K63-Ub-chain and NZF domain of TAB2/3. Response: We appreciate the reviewer's concern. We decreased the dose of LPS and performed several new assays. In sublethal dose of 10 mg/kg LPS only 1 mouse died in WT group (1/6) compared to 5 mice died in KO group (5/6) in 48 h, and the difference between these two groups is statistically significant (Fig.7a) . In another experiment, we intraperitoneal inject 5 mg/kg LPS at day 0 followed with 50 mg/kg intraperitoneal injection of LPS at day 3 (Supplementary Fig. 11a ). The data showed that all 7 WT mice remained alive while 4 out of 7 KO mice died within 144 h.
We appreciate the reviewer's suggestion to evaluate the response of mice to a sublethal dose of TNF. As it's inconvenient to get murine Tnf-α, we chose another inflammatory agent HKLM (heat killed Listeria Monocytogenes) to do the experiment by instead. At a dosage of 2×10 12 CFU/mouse, intraperitoneal injection of HKLM killed 4 out of 7 KO mice within 7 days while the WT mice were all live (Fig.7d) . These results supported our conclusion that Cypj protected mice from acute systematic inflammation.
TNFα should be replaced by TNF (since TNFβ has been renamed to LT).
Response: We thank the reviewer's suggestion. Both TNF-α and TNF are used to describe this cytokine in scientific papers. After carefully searching the PubMed website, we found that TNF-α is used more widely in inflammation-related papers. So we did not make the change in the revised manuscript.
Page 7, lines 139 and 144 : treatment of cells with Il-1β (and not IL-6).
Response: We apologize for the mistakes. They are corrected in this revised manuscript (Page 8, lines 1 and 5).
